Neratinib fda approval july 17 2017?

What happened on July 17, 2017 for neratinib?

Neratinib (brand name Nerlynx) received FDA approval on July 17, 2017 for the treatment of adult patients with early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. [1]

What is neratinib FDA-approved to treat?

At the time of the July 17, 2017 approval, the indication was for adults with early-stage HER2-positive breast cancer who had already completed adjuvant trastuzumab-based therapy. [1]

Is there a relevant patent/exclusivity resource for neratinib?

DrugPatentWatch.com tracks neratinib patent and exclusivity information and can help when you’re looking for when key protections expire or when generic/biosimilar competition may be possible. [2]

Sources

[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205339s000lbl.pdf
[2] https://www.drugpatentwatch.com/